What do systematic reviews say?

Stem cell therapy vs peripheral therapy with granulocyte colony‐stimulating factor

It is very uncertain whether stem cell therapy (any type) changes all‐cause mortality compared with peripheral therapy with granulocyte colony‐stimulating factor (very low certainty).

• Stem cell therapy for dilated cardiomyopathy 2021 · Cochrane Headline outcomes only
  RR 0.46 [0.16, 1.31]
  3 studies · 195 participants
  Very low

Stem cell therapy vs control

It is very uncertain whether stem cell therapy changes all‐cause mortality compared with control (very low certainty).

• Stem cell therapy for dilated cardiomyopathy 2021 · Cochrane Headline outcomes only
  RR 0.84 [0.54, 1.31]
  7 studies · 361 participants
  Very low

Thrombopoietin mimetics vs placebo or usual care

• Alternatives, and adjuncts, to prophylactic platelet transfusion for people with haematological malignancies… 2016 · Cochrane Headline outcomes only
  no estimate extracted
  4 participants
  GRADE not reported

Intervention not reported

The review found no eligible studies for this question.

• Alternatives, and adjuncts, to prophylactic platelet transfusion for people with haematological malignancies… 2016 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

It is very uncertain whether the intervention changes all‐cause mortality at 31 to 100 days (very low certainty).

• Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies treated… 2024 · Cochrane Headline outcomes only
  RR 1 [0.27, 3.7]
  3 studies · 451 participants
  Very low

Intervention not reported

• Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies treated… 2024 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 84 participants
  Very low